COGNITE
6.10.2020 13:02:12 CEST | Business Wire | Press release
Cognite , a leader in industrial innovation, will host its third annual global conference “Ignite Talks: Industrial Intelligence Augmented: Reimagining How Minds and Machines Work Together” from Oct. 27-29, 2020. The free virtual event will feature global leaders and innovators who are driving industries and supply chains toward a more innovative, data-driven, sustainable future.
“The world is at a technological, economic, and environmental crossroads like never before, and we are looking forward to discussing pressing issues among some of the industry’s best,” said John Markus Lervik, Cognite CEO.
The full agenda for this free online conference can be found here and at www.cogniteignite.com .
Day-by-day overviews and panel highlights are listed below:
October 27: Igniting Industrial Transformation: Europe & Norway’s Leading Role
Opening day spotlights how leaders in Europe are melding minds and machines, and inspiring a transformation of heavy-asset industries and supply chains. Panel highlights:
-
What's Next for the Global Energy Transition
: The energy transition is here. Can the oil and gas industry adapt, or is it the end of the industry as we know it?
- Speakers: Bernard Looney, CEO, BP; Ahmad A. Al-Sa’adi, SVP of Technical Services, Saudi Aramco; Øyvind Eriksen, President and CEO, Aker ASA
-
Reinventing Industrial Supply Chains Post-COVID Through Digital Innovation:
2020 has presented the world with a chance to rethink global supply chains. How do we seize the opportunity?
- Speakers: Sameer Kalra, President Marine Division, Alfa Laval; Victoria Van Camp, CTO, SKF
October 28: America’s Industrial Transformation
The technology prowess of the United States and raw innovative capacity is unmatched, and its heavy-asset industries are taking steps to leverage technology at scale in order to jump-start digital transformations. What will it take to succeed, what role does technology play? Panel highlights:
- America’s Energy Transition - in partnership with Axios: A live, virtual event, featuring in-depth 1:1 discussions with industry leaders and policymakers on the development of renewable energy in the US, how the coronavirus pandemic has affected energy patterns, and what’s next for the US oil & gas industry. This panel will be hosted by Axios energy and climate change reporter Amy Harder.
-
Industry Under Siege: A New Era of Industrial Cybersecurity:
Sophisticated cybercriminals are setting their sights on industry. How can industrial companies digitalize operations while minimizing risk?
- Speakers: Ron Brash, Director of Cyber Security Insights, Verve Industrial Protection; Tomomi Aoyama, Head of Business Development UK, Nihon Cyber Defence
-
Navigating the Digital Transition to Renewable Energy
- Speakers: Ashtad Engineer, VP Digital & Transformation, Adani; Astrid Skarheim Onsum, CEO, Aker Offshore Wind
October 29: Driving a Global Transformation from the Bottom Up
The domains and technologies behind the scenes are the real drivers of industrial transformation. The final day gives an insider's view into technology adoption, empowering users with data and domain-specific insights into subsurface and exploration, detection and warning, ocean data, sustainability, and more. Panel highlights:
-
Operationalize and Scale Models and Applications with Trusted Industrial Data:
Data issues are still holding back digitalization initiatives. Experts from Forrester and Wintershall Dea explain how to break down barriers and generate meaningful ROI.
- Speakers: Patrick von Pattay, VP of Intelligent Operations, Wintershall DEA; Paul Miller, Principal Analyst, Forrester
-
Cleaning Up Our Act: Data-Driven Sustainability in Upstream Oil & Gas:
Reducing emissions has become the responsibility of every oil and gas company. BP explains how digitalization is powering its sustainable transformation.
- Speaker: Rob Kelly, Head of Upstream Digital, BP
-
Waves of Change: Using Data to Advance Ocean Sustainability:
The oceans are under siege. In this session, leading ocean experts explain how industry can use data to turn the tide.
- Speakers: Craig McLean, Assistant Administrator of Oceanic and Atmospheric Research, National Oceanic and Atmospheric Administration; Bjørn Tore Markussen, CEO at Center for the 4th Industrial Revolution for the Ocean
About Cognite
Cognite is a global industrial software-as-a-service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world. Their key product, Cognite Data Fusion (CDF), empowers companies with contextualized OT/IT data to drive industrial applications that increase safety, sustainability, and efficiency, and drive revenue. Visit us at www.cognite.com and follow us on Twitter @CogniteData or at LinkedIn: https://www.linkedin.com/company/cognitedata
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005623/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom